Project Grant R43AI149820

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, supports research to determine how the gastric pathogen Helicobacter pylori utilizes ribosomal silencing to regulate its ribosome population and maintain chronic infections. The $168,414 award to the University of California, Santa Cruz will fund a study to investigate the role of the H. pylori ribosome...

This federal Project Grant award of $481,250.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on inhibiting lipoprotein synthesis in the bacterium Helicobacter pylori. The goal is to develop new antimicrobial treatments, as H. pylori infections can lead to severe diseases like peptic ulcers and gastric cancer, and antibiotic resistance is increasing. The 2-year project...

This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA), under the FDA Research program (CFDA 93.103), provides $245,356 to Perspectum, Inc. to conduct a retrospective, multi-center longitudinal observational study. The study aims to collect and analyze magnetic resonance cholangiopancreatography (MRCP) data to generate 3D models and associated MRCP+ metrics, specifically focused on the MRCP+ metric "number of strictures." The goal is to determine how...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH) under CFDA Program 93.213 - Research and Training in Complementary and Integrative Health, provides $506,000.00 in funding to the Scripps Research Institute in La Jolla, CA from September 13, 2024 to August 31, 2026. The award supports research to develop orally available recombinant peptidoglycan hydrolase therapeutics that can promote intestinal barrier function and protect against enteric...

This federal Project Grant award of $295,881 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Osel, Inc., a biotechnology company based in California, aims to develop a novel antimicrobial approach to treat chemoradiation-resistant cervical cancer. The key objective is to synthesize and characterize the potent bacteriocin GASK7B, which selectively inhibits the pathogenic Lactobacillus iners strain that is linked to decreased survival in cervical cancer patients...

This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) is supporting research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential C. difficile dnaE gene. The $426,875 award, which began on Jul 14, 2025 and runs through Jun 30, 2027, aims to advance this platform technology as a...

This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...